|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We included case-control or cohort studies investigating an association between <i>NAT2, CYP2E1, GST</i> or <i>SLCO1B1</i> polymorphisms and the ATDILI risk in patients with tuberculosis.
|
31375612 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Isoniazid, a constituent of most anti- tuberculosis drug regimens, is metabolized by N-acetyltransferase (NAT2) and cytochrome P450 2E1 (CYP2E1) enzymes.
|
25017831 |
2014 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to determine, for the first time, the frequency of slow acetylators in Moroccan population by genotyping of NAT2 gene variants and determining the genotype c1/c1 for CYP2E1 gene, in order to predict adverse effects of Tuberculosis treatment, particularly hepatotoxicity.
|
25544508 |
2014 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity.
|
24903797 |
2014 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis.
|
24607341 |
2014 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
|
24637014 |
2014 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, a possible association between anti-TB DIH and cigarette smoking, N-acetyltransferase 2 (NAT2), Cytochrome P450 2E1 (CYP2E1) and Cytochrome P450 3A4 (CYP3A4) genotypes was studied in 131 TB Brazilian patients.
|
24793319 |
2014 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study was aimed at exploring the role of tSNPs in CYP2E1 gene in a population-based anti-TB treatment cohort.
|
23460870 |
2013 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to assess the association of N-acetyltransferase 2 (NAT2) and cytochrome P450 2E1 (CYP2E1) gene polymorphism with anti-TB DIH in Western Indian population.
|
23875638 |
2013 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present findings may be explained, in part, by changes in the metabolism of the anti-TB drug isoniazid induced via NAT2 and CYP2E1, a metabolic process known to produce hepatotoxic intermediates.
|
22506592 |
2012 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.
|
23131254 |
2012 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
|
20392357 |
2010 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study was designed to investigate the association of genetic polymorphisms of cytochrome P450 subtype 2E1 (CYP2E1) and glutathione S-transferase mu 1 (GSTM1) with susceptibility to antituberculosis drug-induced hepatotoxicity (ADIH) in Chinese tuberculosis patients.
|
20819434 |
2010 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients.
|
18544910 |
2008 |